A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease

CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease

The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease.

Inclusion Criteria:

• Moderate-to-Severe Alzheimer's disease
• Mini-Mental State Examination (MMSE) Score between 5 to 14, inclusive
• Stable on donepezil for at least 6 months

Exclusion Criteria:

• Other causes of dementia
• Major structural brain disease
• Unstable medical condition or significant hepatic or renal disease